|Table of Contents|

Comparison of short-term and long-term curative effects between hepatic artery infusion chemotherapy and transcatheter arterial chemoembolization in the treatment of stage IIb-IIIa hepatocellular carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 08
Page:
1476-1480
Research Field:
Publishing date:

Info

Title:
Comparison of short-term and long-term curative effects between hepatic artery infusion chemotherapy and transcatheter arterial chemoembolization in the treatment of stage IIb-IIIa hepatocellular carcinoma
Author(s):
SONG Qifeng; HU Ling; LIN Shibu; ZHANG Yizhong
Hepatobiliary and Pancreatic Surgery Department,the First Affiliated Hospital of Hainan Medical College,Hainan Haikou 570100，China.
Keywords:
hepatic artery infusion chemotherapy; transcatheter arterial chemoembolization; hepatocellular
PACS:
R735.7
DOI:
10.3969/j.issn.1672-4992.2023.08.016
Abstract:
Objective:To compare short-term and long-term effects of hepatic artery infusion chemotherapy (HAIC) and transcatheter arterial chemoembolization (TACE) in the treatment of stage IIb-IIIa hepatocellular carcinoma based on the propensity score matching method.Methods:123 patients with hepatocellular carcinoma treated in our hospital from January 2019 to June 2020 were included as the research object.The clinical stage was IIb-IIIa.All patients were divided into HAIC group and TACE group according to different treatment schemes.The patients with the closest propensity score in the two groups were matched by 1∶1 propensity score matching method.The liver function，serum tumor markers before and after treatment，adverse reactions after treatment and short-term efficacy of patients between the two groups were compared.The Kaplan-Meier survival curve was drawn.The Log-tank test was used to compare the 2-year disease progression free survival rate of patients between two groups after treatment.Cox regression analysis was used to obtain independent predictors of disease progression in two years after treatment，focusing on the correlation between different treatment methods and disease progression in two years after treatment.Results:A total of 35 pairs of patients were successfully matched between the two groups.After matching，the age，etiology，physical condition score (EGOC score)，gender，body mass index，liver cirrhosis，Child-Pugh grade，clinical stage，maximum tumor diameter and the balance of tumor number of patients between the two groups were significantly improved.After matching，the AST，ALT，and total bilirubin of the two groups were significantly increased compared with those before treatment，and the alpha fetoprotein (AFP) was significantly decreased compared with those before treatment (P＜0.05).After treatment，AST，ALT，total bilirubin and AFP in HAIC group were significantly lower than those in TACE group (P＜0.05).The proportion of liver function damage in the matched HAIC group was significantly lower than that in the TACE group (P＜0.05).After matching，no patients in the two groups achieved complete remission (CR).The proportion of patients with partial remission (PR) in the HAIC group was significantly higher than that in the TACE group (P＜0.05).The 2-year disease progression free survival rate of patients in the matched HAIC group was higher than that in the TACE group (57.1% vs 31.1%，P＜0.05).The results of multivariate Cox regression analysis showed that the clinical stage，AFP，the treatment method was the independent predictors of disease progression at 2 years after treatment (P＜0.05).Conclusion:Compared with TACE treatment，HAIC treatment has lower degree of liver function damage，higher safety，and higher short-term disease control rate and long-term disease progression free survival rate in patients with IIb-IIIa hepatocellular carcinoma.

References:

［1］韩铭,成军,郭江.基于多数据库联合挖掘研究PTP4A3的表达对肝细胞癌发生发展的影响［J］.中国肝脏病杂志（电子版）,2019,11(1):47-52. HAN Ming,CHENG Jun,GUO Jiang.Study on the influence of PTP4A3 expression on the occurrence and development of hepatocellular carcinoma based on joint mining of multiple databases ［J］ Chinese Journal of Liver Diseases (electronic edition),2019,11 (1):47-52.
［2］刘琳,秦叔逵.分子靶向药物与免疫检查点抑制剂治疗晚期肝细胞癌的研究现状与进展［J］.临床肿瘤学杂志,2019,24(9):839-849. LIU Lin,QIN Shukui.Research status and progress of molecular targeted drugs and immunocheckpoint inhibitors in the treatment of advanced hepatocellular carcinoma ［J］ Journal of Clinical Oncology,2019,24(9):839-849.
［3］ZHANG X，WANG K，WANG M，et al.Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus：a systematic review and meta-analysis［J］.Oncotarget,2017,8(17):29416-29427.
［4］MURUMKAR PR，GHUGE RB，CHAUHAN M,et al.Recent developments and strategies for the discovery of TACE inhibitors［J］.Expert Opin Drug Discov,2020,15(7):779-801.
［5］李晓鹤,魏来.国内外肝细胞癌诊疗指南的比较［J］.中华肝脏病杂志,2019,27(3):236-240. LI Xiaohe,WEI Lai.Comparison of domestic and foreign guidelines for diagnosis and treatment of hepatocellular carcinoma ［J］ Chinese Journal of Liver Diseases,2019,27(3):236-240.
［6］HE M，LI Q，ZOU R，et al.Sorafenib plus hepatic arterial infusion of oxaliplatin，fluorouracil，and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion：a randomized clinical trial［J］.JAMA Oncol,2019,5(7):953-960.
［7］林清锋,林征宇,陈一平,等.Barcelona临床肝癌分期B期亚分期肝细胞癌患者TACE术后生存分析［J］.中国介入影像与治疗学,2019,16(5):285-289. LIN Qingfeng,LIN Zhengyu,CHEN Yiping,et al.Analysis of survival after TACE in patients with Barcelona clinical liver cancer stage B sub stage hepatocellular carcinoma ［J］.Chinese Journal of Interventional Imaging and Therapeutics,2019,16(5):285-289.
［8］YUAN P，WANG F，ZHU G，et al.The clinical efficiency of TACE combined with simultaneous computed tomography-guided radiofrequency ablation for advanced hepatocellular carcinoma［J］.Invest New Drugs,2021,39(5):1383-1388.
［9］刘华江,邓堂,颜运智,等.术前NLR联合AFP对肝细胞癌患者TACE术后预后的预测价值［J］.中国临床医学影像杂志,2019,30(10):716-720,747. LIU Huajiang,DENG Tang,YAN Yunzhi,et al.Predictive value of preoperative NLR combined with AFP for prognosis of hepatocellular carcinoma patients after TACE ［J］.Chinese Journal of Clinical Medical Imaging,2019,30(10):716-720,747.
［10］KONG L，WEI G，LV T，et al.Outcome of TACE treatment in HIV infected patients with hepatocellular carcinoma［J］.Sci Rep,2021,11(1):696.
［11］陈治伟,刘晓光,韩创业,等.肝细胞癌切除术后行经导管肝动脉灌注化疗术患者ALT水平改变相关的单核苷酸多态性位点分析［J］.广西医学,2016,38(12):1629-1633. CHEN Zhiwei,LIU Xiaoguang,HAN Chuangye,et al.Analysis of single nucleotide polymorphisms associated with ALT level changes in patients undergoing transcatheter hepatic artery infusion chemotherapy after resection of hepatocellular carcinoma ［J］.Guangxi Medical Journal,2016,38(12):1629-1633.
［12］LI QJ，HE MK，CHEN HW，et al.Hepatic arterial infusion of oxaliplatin，fluorouracil，and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma：a randomized phase III trial［J］.J Clin Oncol,2022,40(2):150-160.
［13］周黎强,余春慧,赵亮.肝动脉灌注化疗术与口服索拉非尼治疗晚期肝癌的疗效［J］.临床医学研究与实践,2018,3(18):24-25. ZHOU Liqiang,YU Chunhui,ZHAO Liang.Efficacy of hepatic artery infusion chemotherapy and oral sorafenib in the treatment of advanced liver cancer ［J］.Clinical Medical Research and Practice,2018,3(18):24-25.
［14］DATTA J，NARAYAN RR，KEMENG NE，et al.Role of hepatic artery infusion chemotherapy in treatment of initially unresectable colorectal liver metastases：a review［J］.JAMA Surg,2019,154(8):768-776.
［15］冯超,赵剑波,陈勇,等.原发性肝癌切除术后预防性经肝动脉介入治疗：肝动脉化疗栓塞术和化疗灌注术比较［J］.介入放射学杂志,2014,23(8):679-682. FENG Chao,ZHAO Jianbo,CHEN Yong,et al.Preventive transcatheter arterial interventional therapy after resection of primary liver cancer:comparison between transcatheter arterial chemoembolization and chemoperfusion ［J］.Journal of Interventional Radiology,2014,23(8):679-682.
［16］LYU N，WANG X，LI JB，et al.Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma：a biomolecular exploratory，randomized，phase III trial (FOHAIC-1)［J］.J Clin Oncol,2022,40(5):468-480.

Memo

Memo:
海南省卫生健康行业科研项目（编号：22A200031）
Last Update: 1900-01-01